PTD - Peptech Limited

[boults_4545]

Huntley's now have PTD recommended as a buy. Price is at it's lowest since nov 2005, what do u guys think?

cheers,
b

 

[Dutchy3]

Hi Boults

Took a marginally profitable dayly position in this one a while back and moved on.

Typically didn't bother to follow any of my rules and did not really look at the weekly at the time some tied up capital is what was ultimatley a disappointing trade. Was coming off a few good positions, so, typically I though I was infalabile at the time.

Saw the weekly though!

Tell you what .... I get a BIG WHITE close through that long red downtrend line and I'll be long

 

[Dutchy3]

Thought I'd do a zoom on this one ... No doubts the forum thinks I'm mad to follow this stock ... THIS SITUATION CAN NOT LAST ... indeed it may fail and drop below 120 ... or it will be one of the 'suprises' of 2006/07 .... waiting for the signal

 

[x2rider]

hi dutchy
It's getting an Aim listing on the 15/12 2006 so might start to se a bit of a rise over the next couple of weeks
Cheers martin

 

[rub92me]

Well, something is up alright. In a trading halt since last Friday.
Someone wants in on the action, check out the pre-open for this one. An order for 250,000 for 75% above the price and plenty of buy depth to follow..

 

[rub92me]

Ah, I know what's up. From the SMH this morning:

Peptech sells UK researcher for $178m
Kirsty Simpson
December 11, 2006
SYDNEY biotechnology group Peptech is poised to pocket $178 million after the sale of one of its major assets, a one-third stake in British antibodies researcher Domantis, to multinational GlaxoSmithKline.
GSK will pay a total of $575 million for Domantis, in a deal that was unveiled late on Friday night and is expected to be completed in January.
Peptech chairman Mel Bridges said the company would realise a gain of $138.2 million for its stake, after investing $40 million in the privately held British company in three tranches between 2001 and late 2005.
Other joint venture partners include a Mitsubishi subsidiary and Europe's largest biotech, Novo Nordisk.
"This is an outstanding result, particularly given the largely pre- clinical stage of Domantis's development pipeline," Mr Bridges said.
The windfall will be set aside for acquisitions and clinical trials. One of Peptech's most promising auto-immune drugs, PN0621 (supplied by Domantis) enters costly stage one clinical trials next year.
Peptech recently unveiled an aggressive growth strategy, revolving around rising drug development spending, and further acquisitions - there were two small purchases last year.
Chief executive Dr John Kiplin said the company also remained open to mergers, and had spoken to more than a hundred companies during the course of its recent buying spree.
Peptech considered its Domantis investment one of its five major assets, but Dr Kiplin said the sale would not affect its commercial collaborative relationship with Domantis, allowing Peptech to select two further therapeutic targets for Domantis to research.
Peptide shares closed on Friday at $1.30.

 

[Dutchy3]

Damm I good ... totally untradeable of course ... still plenty more out there!

 

[Gurgler]

Biotechnology company Peptech Ltd has appointed Citigroup to advise it on several approaches made by private equity firms and other biotechnology companies

up 14.5 cents or 8.15 per cent to $1.925

 

[Crash]

Peptech Ltd has announced a $137.7 million half yearly profit, a jump of 2,415 per cent on the previous year, and a record for the company.

And up on open this morning.

 

[rub92me]

Bit of a blow-off sale (high volume, dipped to a long term low and came back above the open) yesterday after a 6 month slide. I'll be watching this over the next couple of days/weeks. If it moves up from here and breaks through 1.30 again I may hop on.